Drug Trial Radar · NCT06128733
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,215
Actual
Start
Oct 31, 2023
Primary completion
Aug 27, 2025
Study completion Aug 27, 2025
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 25 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.
Conditions
- Meningococcal Immunisation
- Healthy Volunteers
Interventions
Pentavalent Meningococcal ABCYW vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
MenACYW conjugate vaccineBiological
Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
Meningococcal group B vaccineBiological
Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
Meningococcal group B vaccineBiological
Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
Meningococcal group B vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
MenACYW conjugate vaccineBiological
Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)
PlaceboBiological
Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
MenABCYW conjugate vaccineBiological
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
- Number of participants with solicited injection site reactions or systemic reactionsTime frame: Within 7 days after each vaccination
- Number of participants with unsolicited AEsTime frame: Within 30 days after each vaccination
- Number of participants with serious adverse events (SAEs)Time frame: From baseline up to 12 months
- Number of participants with medically attended adverse events (MAAEs)Time frame: From baseline up to 12 months
- Number of participants with out-of-range biological test resultsTime frame: Before each vaccination up to 7 days after primary vaccination visits in the sentinel cohorts (the first 5 participants enrolled in each vaccine group) of each age group
- hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse pre-dose and 1 month after the second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
- hSBA meningococcal serogroups A, C, W, and Y antibody titers pre-dose and 1 month after the second dose in adolescent participantsTime frame: Day 211 (for Group 1 to 7)
- Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 31 Day 211 (for Group 1 to 7)
- Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y in adolescent participantsTime frame: Day 01 (pre-dose) Day 211 (for Group 1 to 7)
- hSBA meningococcal serogroup B seroresponse pre-dose and 1 month after second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
- Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 pre-dose 1 and 1 month post-second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
- Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 pre-dose 1 and 1 month post-second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
- Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) pre-dose 1 and 1 month post-second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
- Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all serogroups B (reference MenB strains) in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
Locations
47 sites in 2 countries. Site status is shown where the registry gives one.
Accel Research Site - Birmingham Clinical Research Unit- Site Number : 8400080
Birmingham, Alabama
Lakeview Clinical Research Site Number : 8400029
Guntersville, Alabama
Alliance for Multispecialty Research- Phoenix- Site Number : 8400056
Tempe, Arizona
Harrisburg Family Medical Center Site Number : 8400070
Harrisburg, Arkansas
Smart Cures Clinical Research Site Number : 8400072
Anaheim, California
Hope Clinical Research, LLC- Site Number : 8400001
Canoga Park, California
Apex Research Group Site Number : 8400071
Fair Oaks, California
Velocity Clinical Research-Washington DC Site Number : 8400102
Washington D.C., District of Columbia
Accel Clinical Research-Deland Clinical Research Unit- Site Number : 8400081
DeLand, Florida
SIMEDHealth, LLC- Site Number : 8400045
Gainesville, Florida
Accel Research Sites-St. Petersburg-Largo- Site Number : 8400082
Largo, Florida
South Florida Research Organization Site Number : 8400086
Medley, Florida
Life Arc Research-Miami Site Number : 8400094
Miami, Florida
Charisma Medical and Research center Site Number : 8400097
Miami Lakes, Florida
Accel Research - Nona Pediatric Center Site Number : 8400079
Orlando, Florida
Ormond Beach Clinical Research- Site Number : 8400073
Ormond Beach, Florida
Palm Harbor Dermatology- Site Number : 8400030
Tampa, Florida
PAS Research Site Number : 8400032
Tampa, Florida
VICIS Clinical Research-Tampa Site Number : 8400065
Tampa, Florida
Leavitt Clinical Research-Idaho Falls- Site Number : 8400075
Idaho Falls, Idaho
Snake River Research, PLLC- Site Number : 8400100
Idaho Falls, Idaho
AES Peoria- Site Number : 8400090
Peoria, Illinois
AMR Evansville Site Number : 8400062
Evansville, Indiana
AMR - Newton- Site Number : 8400104
Newton, Kansas
~Kentucky Pediatics / Adult Research- Site Number : 8400009
Bardstown, Kentucky
Michael W. Simon, MD, PSC- Site Number : 8400026
Lexington, Kentucky
Vida Clinical Studies Site Number : 8400084
Dearborn Heights, Michigan
Vida Clinical Studies- Site Number : 8400084
Dearborn Heights, Michigan
Be Well Clinical Studies- Site Number : 8400077
Lincoln, Nebraska
Alivation Research (Primary Care) Site Number : 8400046
Lincoln, Nebraska
Quality Clinical Research, Inc.- Site Number : 8400074
Omaha, Nebraska
Velocity Clinical Research, Omaha- Site Number : 8400066
Omaha, Nebraska
Velocity Clinical Research-Albuquerque- Site Number : 8400101
Albuquerque, New Mexico
Prime Global Research, Inc. Site Number : 8400043
The Bronx, New York
Monroe Biomedical Research - Site Number : 8400099
Monroe, North Carolina
SPICA Clinical Research Site Number : 8400098
Columbia, South Carolina
Coastal Carolina Research Center - N Charleston- Site Number : 8400050
North Charleston, South Carolina
Tribe Clinical Research at Parkside Pediatrics-Five Forks Site Number : 8400049
Simpsonville, South Carolina
Pediatric Clinical Trials Tullahoma- Site Number : 8400020
Tullahoma, Tennessee
New Horizon Medical Group-Houston Site Number : 8400069
Houston, Texas
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.